On ECHEMI
Home > Drugs > Xi`an Han Feng Pharmaceutical Co., Ltd.
Xi`an Han Feng Pharmaceutical Co., Ltd.
  • Founded in:

    2003-03-11
  • Country:

    China China
  • Address:

    No. 15, Wenji Road, Lantian County Industrial Park
  • Tax NO.:

    91610122742829723D
  • Registered Funds:

    25 million yuan
  • Email:

Related Drugs
Puerarin Injection
8-β-D-Glucopyranose-4',7-dihydroxyisoflavone
Name Description Content CAS NO. Registered Holders
Puerarin

It is a vasodilator that can dilate coronary arteries and cerebral blood vessels, reduce myocardial oxygen consumption, improve microcirculation and resist platelet aggregation. Animal experiments have shown that: 1. The various total flavonoid compounds in Pueraria root can relax smooth muscles, while the contractile components may be substances such as choline, acetylcholine and carbazine R; 2. Pueraria root has a certain antihypertensive effect on normal and hypertensive animals; 3. Pueraria root total flavonoids and puerarin have a significant dilating effect on coronary arteries, which can dilate normal and spasmodic coronary arteries. After intravenous injection of 30mg/Kg, coronary blood flow can increase by 40% and vascular resistance can decrease by 29%; 4. Puerarin can also inhibit the release of 5-HT in platelets induced by thrombin.

More

It is a vasodilator that can dilate coronary arteries and cerebral blood vessels, reduce myocardial oxygen consumption, improve microcirculation and resist platelet aggregation. Animal experiments have shown that: 1. The various total flavonoid compounds in Pueraria root can relax smooth muscles, while the contractile components may be substances such as choline, acetylcholine and carbazine R; 2. Pueraria root has a certain antihypertensive effect on normal and hypertensive animals; 3. Pueraria root total flavonoids and puerarin have a significant dilating effect on coronary arteries, which can dilate normal and spasmodic coronary arteries. After intravenous injection of 30mg/Kg, coronary blood flow can increase by 40% and vascular resistance can decrease by 29%; 4. Puerarin can also inhibit the release of 5-HT in platelets induced by thrombin.

3681-99-0 15
Lidocaine Hydrochloride Injection
The main ingredient of this product is lidocaine hydrochloride. Its chemical name is N-(dichloroxylyl)-2-(diethylamino)acetamide hydrochloride monohydrate.
Name Description Content CAS NO. Registered Holders
Lidocaine hydrochloride

This product is an amide local anesthetic. After blood absorption or intravenous administration, it has obvious biphasic effects of excitation and inhibition on the central nervous system, and there may be no precursor excitation. When the blood concentration is low, analgesia and drowsiness occur, and the pain threshold increases; with increasing doses, the effect or toxicity increases, and it has an anticonvulsant effect at sub-toxic blood concentrations; convulsions may occur when the blood concentration exceeds 5μg·ml-1. At low doses, it can promote the outflow of K in myocardial cells, reduce the autonomy of the myocardium, and have an anti-ventricular arrhythmia effect; at therapeutic doses, it has no obvious effect on the electrical activity of myocardial cells, atrioventricular conduction, and myocardial contraction; further increases in blood concentrations can cause a slowing of the heart conduction velocity, atrioventricular conduction block, inhibition of myocardial contractility, and a decrease in cardiac output.

More

This product is an amide local anesthetic. After blood absorption or intravenous administration, it has obvious biphasic effects of excitation and inhibition on the central nervous system, and there may be no precursor excitation. When the blood concentration is low, analgesia and drowsiness occur, and the pain threshold increases; with increasing doses, the effect or toxicity increases, and it has an anticonvulsant effect at sub-toxic blood concentrations; convulsions may occur when the blood concentration exceeds 5μg·ml-1. At low doses, it can promote the outflow of K in myocardial cells, reduce the autonomy of the myocardium, and have an anti-ventricular arrhythmia effect; at therapeutic doses, it has no obvious effect on the electrical activity of myocardial cells, atrioventricular conduction, and myocardial contraction; further increases in blood concentrations can cause a slowing of the heart conduction velocity, atrioventricular conduction block, inhibition of myocardial contractility, and a decrease in cardiac output.

6108-05-0 45
Danshen injection
Salvia miltiorrhiza.
Name Description Content CAS NO. Registered Holders
Salvia Root P.E Tanshinone IIA 20%

No specific pharmacological information is provided

More

No specific pharmacological information is provided

0
Danshen injection
Salvia miltiorrhiza.
Name Description Content CAS NO. Registered Holders
Salvia Root P.E Tanshinone IIA 20%

Extract from the above information

More

Extract from the above information

0
Oxytetracycline Hydrochloride Tablets
The main ingredient of this product is oxytetracycline hydrochloride, and its chemical name is 6-methyl-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-naphthacenecarboxamide hydrochloride.
Name Description Content CAS NO. Registered Holders
Oxytetracycline hydrochloride

Tetracycline antibiotics are broad-spectrum antibacterial agents, sensitive to many rickettsia, mycoplasma, chlamydia, spirochetes, amoebas and some malarial parasites. Enterococci are resistant to them. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, Vibrio, Brucella, Campylobacter, Yersinia, etc. are sensitive to this product. It has certain antibacterial activity against gonococci and meningococci, but penicillin-resistant gonococci are also resistant to oxytetracycline. Common clinical pathogens are seriously resistant to oxytetracycline, including Gram-positive bacteria such as Staphylococcus and most Gram-negative rods. There is cross-resistance between different varieties of tetracycline antibiotics.

More

Tetracycline antibiotics are broad-spectrum antibacterial agents, sensitive to many rickettsia, mycoplasma, chlamydia, spirochetes, amoebas and some malarial parasites. Enterococci are resistant to them. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, Vibrio, Brucella, Campylobacter, Yersinia, etc. are sensitive to this product. It has certain antibacterial activity against gonococci and meningococci, but penicillin-resistant gonococci are also resistant to oxytetracycline. Common clinical pathogens are seriously resistant to oxytetracycline, including Gram-positive bacteria such as Staphylococcus and most Gram-negative rods. There is cross-resistance between different varieties of tetracycline antibiotics.

2058-46-0 24
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.